The enzyme was doing something else entirely, hidden in plain sight.
HSL enzyme has a previously unknown role inside fat cell nuclei that maintains optimal body fat levels and prevents metabolic disease, challenging decades of scientific understanding. The discovery explains why HSL-deficient patients develop lipodystrophy instead of obesity, revealing both conditions stem from dysfunctional fat cells with serious metabolic consequences.
- Hormone-sensitive lipase (HSL) discovered in the 1960s has a previously unknown role in fat cell nuclei
- HSL-deficient patients develop lipodystrophy, not obesity, revealing both conditions stem from dysfunctional fat cells
- 2.5 billion people worldwide affected by obesity and related metabolic diseases
- Study published in Cell Metabolism by Dominique Langin's team at University of Toulouse
Researchers reveal that hormone-sensitive lipase (HSL), known for 60 years, has a dual function regulating fat cell health in the nucleus, opening new therapeutic pathways for obesity and metabolic diseases affecting 2.5 billion people globally.
For sixty years, scientists thought they understood what hormone-sensitive lipase did. The enzyme, known since the 1960s, was the workhorse that broke down stored fat in our bodies, releasing energy when we needed it. That understanding was foundational to how researchers thought about obesity, metabolism, and the machinery of weight gain and loss. Then a team led by Dominique Langin at the University of Toulouse found something that upended the whole picture: the enzyme was doing something else entirely, something hidden, something that had been operating in plain sight all along.
Langin's group discovered that hormone-sensitive lipase—or HSL—lives in two places inside fat cells, and it does two very different jobs depending on where it is. Everyone knew about its work on the surface of fat droplets, where it breaks down stored triglycerides. But the researchers found HSL also resides deep inside the cell nucleus, where it acts as a regulator, a kind of molecular thermostat that keeps the body's fat stores in balance and prevents metabolic disease. The finding, published in Cell Metabolism, suggests that HSL is far more sophisticated than anyone had realized—a dual-function protein that manages fat tissue health from the inside out.
The discovery emerged from careful detective work. Jérémy Dufau and his colleagues traced where HSL actually goes inside fat cells and found it accumulating in the nucleus through interactions with a protein called SMAD3, which responds to growth factor signaling. When HSL gets chemically modified through a process called phosphorylation, it leaves the nucleus and returns to its fat-breaking duties elsewhere in the cell. This movement—in and out of the nucleus—appears to be the key to the enzyme's regulatory power. In the nucleus, HSL associates with many other proteins and orchestrates a program that maintains the right amount of fat tissue and keeps fat cells functioning properly.
The real insight came from studying what happens when HSL is absent. Patients born without this enzyme don't become obese, as one might expect. Instead, they develop lipodystrophy—a condition where the body loses its ability to store fat properly, leading to severe metabolic complications. This paradox had puzzled researchers for years. Now it makes sense: HSL isn't just about breaking down fat. It's about maintaining the delicate balance that keeps fat tissue healthy. Without it, cells can't regulate themselves. With too much of it in the nucleus, as happens in obese mice, the system goes awry in a different direction. Both obesity and lipodystrophy, it turns out, are diseases of broken fat cells—opposite problems with the same root cause.
The research reveals that HSL levels in the nucleus change depending on what the body is doing. During high-fat eating, HSL accumulates in the nucleus. During fasting, it recedes. This dynamic movement suggests the enzyme is responding to metabolic signals, adjusting fat tissue behavior in real time. The enzyme can also regulate energy production in the mitochondria and influence how fat tissue structures itself, doing opposite things depending on its location in the cell. It's a level of sophistication that explains why simply blocking or boosting HSL has never been a straightforward path to treating obesity.
With 2.5 billion people worldwide living with obesity or overweight, and both conditions linked to serious cardiovascular and metabolic complications, the implications are substantial. Understanding HSL's dual role opens new possibilities for intervention. Rather than trying to shut down fat breakdown or force fat storage, researchers might now target the regulatory function—helping cells maintain their own equilibrium. The same insight could help patients with lipodystrophy, where the problem is the opposite but the solution might involve the same molecular machinery. The enzyme that seemed simple for six decades has revealed itself to be far more nuanced, and that nuance might be exactly what medicine needs.
Notable Quotes
HSL has been known since the 1960s as an enzyme that mobilizes fats, but now we know it also plays an essential role in the nucleus of fat cells, where it helps maintain healthy fat tissue.— Dominique Langin, University of Toulouse
In the nucleus of fat cells, HSL can associate with many other proteins and participate in a program that maintains an optimal amount of fat tissue and keeps fat cells healthy.— Jérémy Dufau, research coauthor
The Hearth Conversation Another angle on the story
So for sixty years, scientists thought they had this enzyme figured out. What made them suddenly realize they were wrong?
They started looking at where the enzyme actually goes inside the cell. They'd always known it worked on the surface of fat droplets, breaking things down. But when they traced it carefully, they found it also sitting in the nucleus, doing something completely different—regulating, not breaking.
And that changes everything about how we think about obesity?
It does, because it explains something that never made sense before. People born without this enzyme don't get fat. They get the opposite disease—they can't store fat at all. That seemed backwards. Now we know both problems come from the same broken system, just broken in different directions.
So the enzyme is like a thermostat, not just a furnace.
Exactly. It's not just about burning fuel. It's about maintaining the right temperature, the right balance. When it's in the nucleus, it's telling fat cells how to behave. When it's somewhere else, it's doing the actual work of breaking things down.
Does that mean we could treat obesity by just moving the enzyme around, or controlling where it goes?
That's the possibility now. Instead of trying to block it or boost it globally, you might be able to influence where it goes, what it does, when. You're working with the body's own regulatory system instead of against it.
And lipodystrophy patients—the ones who can't store fat—could benefit from the same insight?
Yes. If you understand what makes the enzyme work properly in one direction, you might be able to help it work in the other. Both diseases are about fat cells that don't function right. The fix might be the same tool, just applied differently.